At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
PTC is a science-led, global biopharmaceutical company focused on the discovery, d...
PTC is a science-led, global biopharmaceutical ...
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on ...
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a bi...
Love Goodly is on a mission to help women love their bodiesâŚ.and feel good about...
Love Goodly is on a mission to help women love ...
Translate Bio is a leading mRNA therapeutics company developing a new class of pot...
Translate Bio is a leading mRNA therapeutics co...
Join the National Investor Network and get the latest information with your interests in mind.